Professor John Snowden

BSc, MBChB, MD, FRCP (London), FRCP (Edin), FRCPath, DTM&H

Department of Oncology and Metabolism

Honorary Professor

Consultant Haematologist

Director of Blood and Marrow Transplantation (BMT) Programme, Sheffield Teaching Hospitals NHS Foundation Trust.

John Snowden, male sits at desk with microscope
john.snowden1@nhs.net
+44 114 271 3357

Full contact details

Professor John Snowden
Department of Oncology and Metabolism
Royal Hallamshire Hospital
Glossop Road
Sheffield
S10 2JF
Profile

I trained as an undergraduate in the University of Leeds, and as a postgraduate in the UK, Australia and New Zealand. I have been Consultant Haematologist and Director of the Blood and Marrow Transplant (BMT) Programme in Sheffield, UK since 2002.

Nationally, I have held several key leadership roles in BMT and haemato-oncology, including Clinical Lead for various NICE Guidelines and Chair of the NHS England Clinical Reference Group for BMT (2016-20). From 2017-20, I was Chair of the Intercollegiate Committee on Haematology to the Royal College of Physicians and Royal College of Pathologists. Since 2019, I have been co-Lead clinician for Haematology-Oncology in the NHS England Genomic Laboratory Hub (GLH) for North East & Yorkshire region. I am currently President of the British Society of Blood and Marrow Transplantation and Cellular Therapy (2021-22). 

Internationally, I have a long association with the European Society for Blood and Marrow Transplantation (EBMT) and the international accreditation organisation, ‘JACIE’, including JACIE Medical Director (2012-16) and Chair of the JACIE Committee (2015-20). I have been a member of the EBMT Board and Scientific Council as Autoimmune Diseases Working Party Chair (2016-20) and now as EBMT Secretary (2020-24). 

Academically, I have contributed to the fields of BMT, haematology-oncology and autoimmunity with authorship of over 300 publications (Google Scholar H index >60), along with clinical trials, grant awards, educational meetings, teaching, supervision, examination, journal editorship and scientific peer review. I have been awarded honorary professorships by The University of Sheffield and University College London.

Current/recent appointments

  • Consultant Haematologist & Director of Blood and Marrow Transplantation (BMT) Programme, Sheffield Teaching Hospitals NHS Foundation Trust (from September 2002 to present).
  • Honorary Professor, Department of Oncology & Metabolism, University of Sheffield, UK (2013-16, renewed 2016-19, renewed 2019-22).
  • Secretary to the European Society for Blood and Marrow Transplantation (EBMT, 2020-24).
  • President of British Society of Blood and Marrow Transplantation & Cellular Therapy (BSBMTCT, 2021-22).
  • Chair of the Intercollegiate Committee on Haematology (ICH) to the RCP (London) and RCPath (2017-20).
  • Co-Lead Clinician for Haematology-Oncology in the NHS England Genomic Laboratory Hub (GLH) for North-East & Yorkshire (NEY) region, appointed March 2019.
  • British Society for Haematology (BSH), Elected Member of Board of Trustees, 2022-25.
Qualifications
  • BSc Pathology, First Class Honours, University of Leeds, 1987.
    • Willis Prize in Pathology, University of Leeds 1987.
  • MBChB Medicine, University of Leeds, 1989.
    • Paul Fitton Prize in Anaesthesia, Association of Anaesthetists, UK 1988.
    • Pullen Prize in Obstetrics and Gynaecology, University of Leeds 1989.
    • William MacAdam Prize in Medicine, University of Leeds 1989.
  • Membership of the Royal College of Physicians, MRCP (UK), 1992.
  • Membership of the Royal College of Pathologists, MRCPath, 1999.
  • Doctor of Medicine, MD, University of Leeds, 1999.
  • Specialist Certification in Haematology, 1999.
  • Fellowship of the Royal College of Physicians of London, FRCP (Lond), 2004.
  • Fellowship of the Royal College of Pathologists, FRCPath, 2007.
  • Fellowship of the Royal College of Physicians of Edinburgh, FRCP (Edin), 2019.
  • Diploma in Tropical Medicine & Hygiene, DTM&H, awarded by RCP London 2021.
Research interests

In conjunction with NHS roles, my principal academic areas of interest are:

  • Blood and marrow stem cell transplantation in cancer and non-malignant disorders.
  • Physical and psychological late effects in survivors of cancer treatment and BMT.
  • Multiple myeloma, from cell biology to supportive care and survivorship research.
  • Leukaemia and other haematological cancers.
  • Service development, ‘quality’, accreditation, benchmarking and health economics in haemato-oncology and BMT.

My academic activity is reflected by:

  • Full publication of over 300 medical & scientific articles (Google Scholar H-index >60).
  • Over £8 million in grant awards as co-applicant or chief/principal investigator.
  • Organising numerous national and international conferences.
  • Regular invitations to speak and chair sessions at numerous national & international meetings. 
  • Extensive scientific peer review for respected general and specialist journals.
  • Collaborations with other national and international Haemato-oncology and BMT Programmes.
  • Local Principal Investigator/Chief Investigator and National Co-ordinator roles in multicentre National Cancer Research Institute (NCRI) and industry sponsored clinical research trials.
  • Delivering undergraduate/postgraduate teaching, supervision, training, examination in Sheffield.
  • External examiner for PhD examinations in other Universities (Birmingham, Newcastle, Oxford). 
Publications

Show: Featured publications All publications

Journal articles

All publications

Journal articles

Chapters

Conference proceedings papers

  • Lindsay J, Din S, Hawkey C, Hind D, Irving P, Lobo A, Mahida Y, Moran G, Parkes M, Satsangi J , Subramanian S et al (2021) OFR-9 An RCT of autologous stem-cell transplantation in treatment refractory Crohn’s disease (low-intensity therapy evaluation): ASTIClite. Oral RIS download Bibtex download
  • Styczynski J, Tridello G, Gil L, Ljungman P, Mikulska M, van der Werf S, Knelange N, Averbuch D, Socie G, Veelken H , Dalle J-H et al (2019) Donor EBV-positive serostatus increases the risk of chronic GVHD in patients with non-malignant hematological disorders: Infectious diseases working party EBMT study. BONE MARROW TRANSPLANTATION, Vol. 54 (pp 400-401) RIS download Bibtex download
  • Greco R, Labopin M, Badoglio M, Veys P, Silva J, Abinun M, Gualandi F, Bornhauser M, Ciceri F, Saccardi R , Lankester A et al (2019) Allogeneic hsct for autoimmune diseases: A retrospective study from the ebmt autoimmune diseases, inborn errors and paediatric working parties. BONE MARROW TRANSPLANTATION, Vol. 54 (pp 33-34) RIS download Bibtex download
  • Cesaro S, Tridello G, Knelange NS, Schaap N, Martin M, Snowden J, Malladi R, Ljungman P, Deconinck E, Gedde-Dahl T , Russell NH et al (2019) Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non leukemic patients: An outcome analysis on behalf of IDWP. BONE MARROW TRANSPLANTATION, Vol. 54 (pp 397-399) RIS download Bibtex download
  • Shouval R, Fein JA, Labopin M, Duarte RF, Corbacioglu S, Bader P, Chabannon C, Kuball J, Basak G, de Latour RP , Lankeste A et al (2019) Young HLA-matched unrelated donors are comparable to matched sibling donors in elderly patients receiving reduced-intensity conditioning: an analysis on behalf of the EBMT scientific council. BONE MARROW TRANSPLANTATION, Vol. 54 (pp 602-603) RIS download Bibtex download
  • Burt R, Balabanov R, Snowden J, Sharrack B, Oliveira MC, Nelson F & Burman J (2019) HSCT treatment for multiple sclerosis: Results from the MIST trial. EUROPEAN JOURNAL OF NEUROLOGY, Vol. 26 (pp 978-978) RIS download Bibtex download
  • Greenfield DM, Salooja N, Peczynski C, van der Werf S, Schoemans H, Hill K, Cortelezzi A, Lupo Stanghellini MT, Ozkurt ZN, Arat M , Metzner B et al (2018) Metabolic Syndrome Is Common Following Haematopoietic Cell Transplantation (HCT) and Is Associated with Increased Cardiovascular Disease and Second Cancers: An EBMT Cross-Sectional Non-Interventional Study. Blood, Vol. 132(Supplement 1) (pp 251-251) RIS download Bibtex download
  • Cook G, Parrish C, Yong K, Cavenagh J, Snowden JA, Drayson MT, Garg M, Cairns D, Ashcroft J, Striha A , Hockaday A et al (2018) Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial. Blood, Vol. 132(Supplement 1) (pp 255-255) RIS download Bibtex download
  • Farge D, Snowden JA, Badoglio M, Labopin M, Scherer HU, Del Papa N, Kanz L, Schmalzing M, Martin T, Rovira M , Daikeler T et al (2018) Improving Treatment Related Mortality over Time - Data from the Non-Observational Trial on Autologous Stem Cell Transplantation in Systemic Sclerosis By the EBMT Autoimmune Diseases Working Party (ADWP). Blood, Vol. 132(Supplement 1) (pp 3431-3431) RIS download Bibtex download
  • Lawless S, Iacobelli S, Knelange N, Chevallier P, Blaise D, Milpied N-J, Foà R, Cornelissen JJ, Lioure B, Potter V , Poire X et al (2018) Results of Autologous and Allogeneic Transplantation in Patients with Primary Plasma Cell Leukemia: A Large Retrospective Analysis of the Chronic Malignancies Working Party of the EBMT. Blood, Vol. 132(Supplement 1) (pp 3425-3425) RIS download Bibtex download
  • Das J, Snowden J, Burman J, Freedman M, Atkins H, Bowman M, Burt R, Sarccardi R, Innocenti C, Mistry S , Bell S et al (2018) The use of autologous haematopoietic stem cell transplantation as a first line disease modifying therapy in patients with 'aggressive' multiple sclerosis.. MULTIPLE SCLEROSIS JOURNAL, Vol. 24 (pp 87-88) RIS download Bibtex download
  • Jones GL, Vogt K, Darby F, Mahmoodi N, Hughes J, Greenfield D, Skull J, Lane S, Brauten-Smith G, Yeomanson D , Baskind NE et al (2018) Experience of developing and evaluating a fertility preservation patient decision aid for teenage and adult women with cancer for use in oncology settings, UK (The Cancer, Fertility and Me study). PSYCHO-ONCOLOGY, Vol. 27 (pp 45-45) RIS download Bibtex download
  • Styczynski J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, Mikulska M, Gil L, Cordonnier C, Ljungman P , Averbuch D et al (2018) Lethal infectious complications after hematopoietic stem cell transplantation: progress and challenges in Infectious Diseases Working Party study. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 94-95) RIS download Bibtex download
  • Morley N, Snowden J, Pearce R, Perry J, Paul R, Kirkland K, Lambert J, Malladi R & Peniket A (2018) BEAM versus LEAM conditioning chemotherapy for autologous transplantation in lymphoma. A retrospective study from the BSBMT. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 258-258) RIS download Bibtex download
  • Raj K, Protheroe R, Smith M, Gilleece M, Snowden JA, Uttenthal B, Irvine D, Collin M, Paneesha S, Salim R , Tholouli E et al (2018) Peripheral blood stem cell RIC haploidentical transplantation low incidence of GVHD and non relapse mortality: Preliminary results from the prospective phase II UK Haplo study. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 752-754) RIS download Bibtex download
  • Shouval R, Fein J, Labopin M, Kroger N, Duarte RF, Bader P, Bonini C, Kuball J, Basak G, Dufour C , Lankester A et al (2018) Should Donor Selection be Driven by Disease Risk? A Retrospective Analysis of the EBMT Registry on Behalf of the Acute Leukemia Working Party. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 135-136) RIS download Bibtex download
  • Chalandon Y, Sbianchi G, Hoek J, Apperley J, Itala-Remes M, Markiewicz M, Byrne J, Sengeloev H, Chaudri N, Malladi R , Remenyi P et al (2018) Allogeneic stem cell transplantation in patients with CML-CP in the era of third generation tyrosine kinase inhibitors: a study by the CMWP of the EBMT. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 45-46) RIS download Bibtex download
  • Samuelson C, Alexander T, Daikeler T, Badoglio M, Henes J, Akil M, Skagerlind L, Ehninger G, Jantunen E, Farge D & Snowden JA (2018) Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV): Results of a EBMT Retrospective Survey. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 203-204) RIS download Bibtex download
  • Thorpe AE, Kass-Iliyya L, Jessop H, Chantry A, Hadjivassiliou M, Sharrack B & Snowden JA (2018) Autologous Haematopoietic Stem Cell Transplantation (Auto-HSCT) in Stiff Person Syndrome (SPS): The Sheffield Experience. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 204-205) RIS download Bibtex download
  • Das J, Snowden J, Mistry S, Jessop H, Bowman M, Ismail A, Bell S, Freedman M, Atkins H, Burman J & Sharrack B (2018) The use of Autologous Haematopoietic Stem Cell Transplantation in treatment naive patients with severe multiple sclerosis. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 38-39) RIS download Bibtex download
  • Henes J, Oliveira MC, Labopin M, Badoglio M, Scherer HU, Del Papa N, Daikeler T, Schmalzing M, Schroers R, Martin T , Pugnet G et al (2018) Autologous Stem cell transplantation for progressive systemic sclerosis: an EBMT Autoimmune Disease Working Party prospective non-interventional approach. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 37-38) RIS download Bibtex download
  • Ward KN, Ljungman P, Hoek J, Finke J, Niederwieser D, Einsele H, Fegueux N, Angel Diaz M, Maria Fernandez J, Menard A-L , Collin M et al (2018) Infectious Diseases Working Party Retrospective Study on HHV-6 encephalitis: clinical characteristics and outcome after allogeneic HSCT. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 565-566) RIS download Bibtex download
  • Snowden J, Keen C, Smith L, Skilbeck J, Ross H, Collins K, Simpson S, Dixey J, Walters S, Greenfield D & Mawson S (2018) Is it feasible to conduct a randomised controlled trial of pre-habilitation in multiple myeloma (MM) patients awaiting autologous haematopoietic stem-cell transplantation (AHSCT)? The PREeMPT study. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 343-344) RIS download Bibtex download
  • Greenfield D, Snowden J, Morley N, Wright J, Evans C & DeSilva T (2018) Vaccine preventable diseases: a clinical evaluation of antibody reconstitution after autologous HCT. BONE MARROW TRANSPLANTATION, Vol. 53 (pp 381-382) RIS download Bibtex download
  • Chalandon Y, Sbianchi G, Hoek J, Apperley J, Itala-Remes M, Markiewicz M, Byrne J, Sengeloev H, Chaudri N, Malladi R , Remenyi P et al (2018) Allogeneic stem cell transplantation in patients with CML-CP in the era of third generation tyrosine kinase inhibitors: a study by the CMWP of the EBMT. SWISS MEDICAL WEEKLY, Vol. 148 (pp 4S-4S) RIS download Bibtex download
  • Alexander T, Samuelson C, Daikeler T, Henes J, Skagerlind L, Akil M, Ehninger G, Jantunen E, Farge D & Snowden J (2018) SAT0549 Autologous hematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) – a ebmt retrospective survey. Saturday, 16 JUNE 2018 RIS download Bibtex download
  • Das J, Snowden J, Mistry S, Jessop H, Bell S & Sharrack B (2018) Autologous Haematopoietic Stem Cell Transplantation in Treatment Naive Patients with Rapidly Evolving Severe Multiple Sclerosis. NEUROLOGY, Vol. 90 RIS download Bibtex download
  • Burt RK, Balabanov R, Snowden JA, Sharrack B, Oliveira MC & Burman J (2018) Non-myeloablative hematopoietic stem cell transplantation (HSCT) is superior to disease modifying drug (DMD) treatment in highly active Relapsing Remitting Multiple Sclerosis (RRMS): interim results of the Multiple Sclerosis International Stem cell Transplant (MIST) Randomized Trial. NEUROLOGY, Vol. 90 RIS download Bibtex download
  • Raj K, Protheroe R, Smith M, Gilleece M, Snowden J, Uttenthal B, Irvine D, Collin M, Paneesha S, Salim R , Tholouli E et al (2018) Peripheral blood stem cell RIC haploidentical stem cell transplantation low TRM, low rates of GVHD: Preliminary results from the prospective Phase II single arm UK Haplo study (Bloodwise: 11034). BRITISH JOURNAL OF HAEMATOLOGY, Vol. 181 (pp 13-13) RIS download Bibtex download
  • Brierley C, Castilla-Llorente C, Labopin M, Badoglio M, Rovira M, Ricart E, Dierickx D, Vermeire S, Hasselblatt P, Finke J , Onida F et al (2018) Autologous haematopoietic stem cell transplantation for Crohn's disease: a retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party. JOURNAL OF CROHNS & COLITIS, Vol. 12 (pp S14-S15) RIS download Bibtex download
  • Snowden J, Panes J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P, Hawkey C, Kazmi M , Lindsay J et al (2018) ECCO-EBMT joint paper: autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease: Summary of the ECCO-EBMT joint review. JOURNAL OF CROHNS & COLITIS, Vol. 12 (pp S70-S71) RIS download Bibtex download
  • Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, Gennery A, Kroeger N, Kuball J, Lanza F , Montoto S et al (2017) Use of haploidentical stem cell transplantation continues to increase, the 2015 European society for blood and marrow transplant activity survey report. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S191-S192) RIS download Bibtex download
  • Brierley C, Castilla-Llorente C, Labopin M, Badoglio M, Rovira M, Ricart E, Dierickx D, Vermeire S, Hasselblatt P, Finke J , Onida F et al (2017) Autologous haematopoietic stem cell transplantation (AHSCT) for Crohn's disease (CD): A retrospective study of outcomes from the EBMT autoimmune diseases working party (ADWP). BONE MARROW TRANSPLANTATION, Vol. 52 (pp S418-S418) RIS download Bibtex download
  • Domingo-Domenech E, Boumendil A, Climent F, Sengeloev H, Ljungman P, Wattad M, Arat M, Finel H, Schaap M, Ganser A , Yeshurun M et al (2017) Autologous stem cell transplantation for systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S440-S440) RIS download Bibtex download
  • Shouval R, Fein J, Labopin M, Kroger N, Duarte RF, Bader P, Bonini C, Dreger P, DuFour C, Gennery A , Kuball J et al (2017) Application of the disease risk index for risk stratification of allogeneic hematopoietic stem cell transplantation in a large cohort of the European Society for Blood and Marrow Transplantation (EBMT). BONE MARROW TRANSPLANTATION, Vol. 52 (pp S12-S13) RIS download Bibtex download
  • Kuehl J-S, Snowden J, Aubourg P, Koehler W & Arnold R (2017) HSCT for adult cerebral adrenoleukodystrophy. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S120-S120) RIS download Bibtex download
  • Mapplebeck C, Sharrack B, Kaur H, Ezaydi Y, Jessop H, Pickersgill L, Scott L, Raza M & Snowden JA (2017) EBV and CMV reactivation following autologous haematopoietic stem cell transplantation (HSCT) for autoimmune neurological diseases resolves spontaneously and rarely requires treatment. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S419-S419) RIS download Bibtex download
  • Miller PDE, de Silva T, Leonard H, Goddard K, Anthias C, Hoschler K, Peggs K, Madrigal A & Snowden JA (2017) Viral microneutralization assay to determine seasonal influenza vaccine immunogenicity in the first year post reduced intensity conditioning allogeneic HSCT. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S269-S270) RIS download Bibtex download
  • Greco R, Labopin M, Badoglio M, Veys P, Silva J, Abinun M, Gualandi F, Bornhauser M, Ciceri F, Tobias A , Gennery A et al (2017) Allogeneic HSCT for autoimmune diseases: a retrospective study from the EBMT autoimmune diseases, inborn errors and paediatric working parties. BONE MARROW TRANSPLANTATION, Vol. 52 (pp S42-S42) RIS download Bibtex download
  • Tappenden P, Wang Y, Burman J, Kazmi M, Saccardi R, Bermejo I, Harvey R, Badoglio M, Farge D, Sharrack B & Snowden J (2017) Evaluating the cost-effectiveness of autologous haematopoietic stem cell transplantation (aHSCT) versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison (MAIC). BONE MARROW TRANSPLANTATION, Vol. 52 (pp S41-S41) RIS download Bibtex download
  • Morley N, Kirkwood A, Moorman A, Clifton-Hadley L, Rowntree C, Wrench B, Marwood E, Patrick P, Snowden J, Rijneveld A , Marks D et al (2017) RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKAEMIA. HAEMATOLOGICA, Vol. 102 (pp 31-32) RIS download Bibtex download
  • Galleu A, Deplano S, Szydlo R, Milojkovic D, Bradshaw A, Wynn R, Marks D, Richardson D, Orchard K, Kanfer E , Tholouli E et al (2017) MESENCHYMAL STROMAL CELLS FOR THE TREATMENT OF STEROID-RESISTANT ACUTE GRAFT VERSUS HOST DISEASE: FACTORS INFLUENCING CLINICAL RESPONSES. HAEMATOLOGICA, Vol. 102 (pp 336-337) RIS download Bibtex download
  • Shouval R, Fein J, Labopin M, Kroger N, Duarte RF, Bader P, Bonini C, Dreger P, DuFour C, Gennery A , Kuball J et al (2016) The Disease Risk Index Is a Robust Tool for Allogeneic Hematopoietic Stem Cell Transplantation Risk Stratification: An Independent Validation Study on a Large Cohort of the European Society for Blood and Marrow Transplantation (EBMT). Blood, Vol. 128(22) (pp 988-988) RIS download Bibtex download
  • Olavarria E, Schleuning M, Iacobelli S, Hoek J, Blok H-J, Aljurf M, Afanasyev BV, Volin L, Sengeloev H, Masszi T , Passweg J et al (2016) An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors. Blood, Vol. 128(22) (pp 628-628) RIS download Bibtex download
  • Lawless S, Simona I, van Biezen A, Koster L, Chevallier P, Blaise D, Foà R, Tabrizi R, Schaap NPM, Lenhoff S , Russell NH et al (2016) Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia. Blood, Vol. 128(22) (pp 2293-2293) RIS download Bibtex download
  • Cook G, Carter CR, Brock K, McQuaker G, Snowden JA, Crawley C, Hunter H, Cavenagh JD, Lobb M, Cullen K , Hodgkinson A et al (2016) Immune Biomarkers Identify Sustained Quantitative and Functional Immune Reconstitution in the Setting of Adjunctive Lenalidomide Following T-Depleted RIC-Allo SCT for Multiple Myeloma. Blood, Vol. 128(22) (pp 4585-4585) RIS download Bibtex download
  • Gagelmann N, Iacobelli S, Koster L, Nahi H, Stoppa A-M, Masszi T, Caillot D, Lenhoff S, Udvardy M, Crawley C , Arcese W et al (2016) Impact of Extramedullary Disease in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Study By the EBMT Chronic Malignancies Working Party. Blood, Vol. 128(22) (pp 2266-2266) RIS download Bibtex download
  • Ismail A, Hickman S, Paling D, Phelan J, Havercroft J, Webster S, Alexander HJ, Snowden J & Sharrack B (2016) The impact of the BBC Panorama television programme on public awareness of autologous haematopoietic stem cell therapy (AHSCT) for patients with multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL, Vol. 22 (pp 784-784) RIS download Bibtex download
  • Morley N, Kirkwood A, Moorman A, Smith P, Rowntree C, Wrench B, Marwood E, Patrick P, Snowden J, Rijneveld A , Marks D et al (2016) INITIAL RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA. HAEMATOLOGICA, Vol. 101 (pp 34-34) RIS download Bibtex download
  • Bell S, Kelsey P, Jessop H, Snowden J & Sharrack B (2016) The Use of Autologous Haemopoietic Stem Cell Transplantation in Treating Patients with Rapidly Evolving Severe Multiple Sclerosis. NEUROLOGY, Vol. 86 RIS download Bibtex download
  • Bell S, Kelsey P, Jessop H, Snowden J & Sharrack B (2016) The Use of Autologous Haemopoietic Stem Cell Transplantation in Treating Patients with Rapidly Evolving Severe Multiple Sclerosis. NEUROLOGY, Vol. 86 RIS download Bibtex download
  • Mohammed MK, Snowden J, Rosario DJ & Munir M (2016) High dose melphalan and autologous stem cell transplantation following urinary bladder reconstruction with ileum: Measures to minimise mucositis. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 178-178) RIS download Bibtex download
  • Cook G, Williams C, Cairns DA, Hockaday A, Cavenagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H , Bird JM et al (2016) A salvage autologous stem cell transplant (ASCT2) induces superior overall survival following bortezomib-containing re-induction therapy for relapsed multiple myeloma (MM): Results from the Myeloma X (Intensive) Trial. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 5-6) RIS download Bibtex download
  • Samuelson CV, Griffin M, Welch E, Went R, Kaul S, Ng JP, Barker H & Snowden JA (2016) Mortality within 30 days of systemic anticancer therapy (SACT) - results of a multi-site audit following the NCEPOD model in the South Yorkshire region. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 34-34) RIS download Bibtex download
  • Ahmedzai SH, Snowden JA, Cox A, Cairns DA, Williams C, Hockaday A, Cavenagh JD, Parrish C, Yong K, Cavet J , Hunter H et al (2016) Balancing therapeutic impact of treatment strategies with quality of life and pain experience in multiple myeloma: New insights into influence of genetic variants. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 132-133) RIS download Bibtex download
  • Ashcroft AJ, Cairns DA, Williams C, Hockaday A, Cavanagh JD, Snowden JA, Parrish C, Yong K, Cavet J, Hunter H , Bird JH et al (2016) Outcomes following salvage autologous stem cell transplant (ASCT2) vs low dose alkylating consolidation (non-transplant consolidation NTC) therapy following bortezomib-containing re-induction for relapsed multiple myeloma (MM) may be dependent on age and symptomatic status initiation of re-induction: Results from the Myeloma X (Intensive) Trial. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 173 (pp 165-165) RIS download Bibtex download
  • Miller PDE, de Silva T, Skinner R, Gilleece M, Peniket A, Hamblin A, Greenfield D, Anthias C, Peggs K, Madrigal A , Snowden JA et al (2016) Routine Vaccination Programme (RVP) Practice after Adult and Paediatric Allogeneic Haematopoietic Stem Cell Transplant (HSCT): A British Society of Blood and Marrow Transplantation (BSBMT) Survey of UK NHS-Based Programmes. BONE MARROW TRANSPLANTATION, Vol. 51 (pp S400-S401) RIS download Bibtex download
  • Holbro A, Baldomero H, Buser A, Chabannon C, Lanza F, Snowden J, Worel N, Sureda A, Badoglio M, Passweg J , Bonini C et al (2016) Graft storage and disposal policies in a large group of european centers: a survey by the cellular therapy and immunobiology working party (CTIWP) of the European Group For Blood And Marrow Transplantation (EBMT). BONE MARROW TRANSPLANTATION, Vol. 51 (pp S50-S51) RIS download Bibtex download
  • Lawless S, Iacobelli S, van Biezen A, Koster L, Chevallier P, Blaise D, Foa R, Tabriz R, Schaap N, Lenhoff S , Russell N et al (2016) Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia. BONE MARROW TRANSPLANTATION, Vol. 51 (pp S18-S19) RIS download Bibtex download
  • Veys P, Danby R, Vora A, Slatter M, Wynn R, Lawson S, Steward C, Gibson B, Potter M, de la Fuente J , Shenton G et al (2016) UK experience of unrelated cord blood transplantation in paediatric patients. British Journal of Haematology, Vol. 172(3) (pp 482-486) RIS download Bibtex download
  • Cook G, Williams C, Cairns DA, Hockaday A, Cavenagh J, Snowden JA, Parrish C, Yong KL, Cavet J, Hunter H , Bird J et al (2015) ASCT2A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial. BLOOD, Vol. 126(23) RIS download Bibtex download
  • Samarasinghe S, Iacobelli S, Knol C, Hamladji R-M, Socie G, Aljurf M, Koh M, Sengeloev H, Dalle J-H, Robinson S , Bacigalupo A et al (2015) Impact of Different In Vivo T Cell Depletion Strategies on Outcomes Following Hematopoietic Stem Cell Transplantation for Idiopathic Aplastic Anaemia: A Study on Behalf of the EBMT SAA Working Party. Blood, Vol. 126(23) (pp 1210-1210) RIS download Bibtex download
  • Guillaume-Jugnot P, Marjanovic Z, Labopin M, Terriou L, Deligny C, Lioure B, Martin T, Leblond V, Pugnet G, Blaise D , Peffault de Latour R et al (2015) Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity. Blood, Vol. 126(23) (pp 1985-1985) RIS download Bibtex download
  • Ashcroft J, Cairns DA, Williams C, Hockaday A, Cavenagh JD, Snowden JA, Parrish C, Yong KL, Cavet J, Hunter H , Bird J et al (2015) Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial. Blood, Vol. 126(23) (pp 1981-1981) RIS download Bibtex download
  • Ahmedzai SH, Snowden JA, Cox A, Cairns DA, Williams CD, Hockaday A, Cavenagh J, Parrish C, Yong KL, Cavet J , Hunter H et al (2015) Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience. Blood, Vol. 126(23) (pp 3180-3180) RIS download Bibtex download
  • Kelsey P, Bell SM, Jessop H, Snowden JA & Sharrack B (2015) AUTOLOGOUS HAEMOPOIETIC STEM CELL TRANSPLANT IN MS: SHEFFIELD COHORT. Journal of Neurology, Neurosurgery & Psychiatry, Vol. 86(11) (pp e4.116-e4) RIS download Bibtex download
  • Snowden J, Badoglio M & Farge D (2015) EBMT Autoimmune Diseases Working Party (ADWP) Database: Activity 1994-2014. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S112-S112) RIS download Bibtex download
  • Greenfield D, Snowden J, Schoemans H, Hill K, Annaloro C, Lupo-Stanghellini MT, Aki Z, Arat M, Metzner B, Turlure P , Han T et al (2015) Metabolic syndrome is common following haematopoietic cell transplantation (HCT) and is associated with increased cardiovascular disease: an EBMT cross-sectional non-interventional study. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S89-S90) RIS download Bibtex download
  • Cesaro S, Tridello G, Volin L, Craddock C, Michallet M, Schaap N, Cornelissen J, Ljungman P, Hunter A, Maertens J , Russell N et al (2015) A retrospective IDWP-ALWP study on Candida infections in allogeneic haematopoietic stem cell transplant patients. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S32-S33) RIS download Bibtex download
  • Collins N, Whittle R, Robertson K, Lunn R, Sills K, Bloor A, Snowden J & Key T (2015) CD34+count and not total nucleated cell count has impact on OS in adult dUCBT. BONE MARROW TRANSPLANTATION, Vol. 50 (pp 5566-5567) RIS download Bibtex download
  • Clay J, Kelsey P, Bell S, Lim C, Helen J, Nicholas R, Silber E, Malik O, Brex P, Muraro P , Sharrack B et al (2015) Autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a UK cohort from two centres. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S61-S61) RIS download Bibtex download
  • Meiring J, De Silva T & Snowden J (2015) A study of adherence to a vaccination schedule following adult allogenic haematopoietic stem cell transplants in UK transplant centre. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S203-S204) RIS download Bibtex download
  • Greenfield D, Shanklin V & Snowden J (2015) Implementing International HCT Late Effects Screening Guidelines in Clinical Practice: Outcomes. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S210-S210) RIS download Bibtex download
  • Hamblin A, Greenfield D, Gilleece M, Salooja N, Kenyon M, Morris E, Glover N, Miller P, Braund H, Peniket A , Shaw B et al (2015) Provision of Long-term Monitoring and Late Effects Services Following Allogeneic HSCT in Adults: A British Society of Blood and Marrow Transplantation (BSBMT) Survey of UK NHS-Based Programmes. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S91-S92) RIS download Bibtex download
  • Thomas SJ, Fisher K, Brown S, Snowden JA, Danson S & Zeidler M (2014) Methotrexate Is a Suppressor of JAK/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling. Blood, Vol. 124(21) (pp 4577-4577) RIS download Bibtex download
  • Oliveira MC, Labopin M, Henes J, Moore J, Del Papa N, Stanciu R, Sakellari I, Schroers R, Scherer HU, Kyrcz-Krzemien S , Daikeler T et al (2014) Does Ex Vivo CD34+ Cell Selection Change the Outcome of Systemic Sclerosis Patients Treated with Autologous Hematopoietic Stem Cell Transplantation (AHSCT), an Adwp EBMT Study?. Blood, Vol. 124(21) (pp 2517-2517) RIS download Bibtex download
  • Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Akay OM, Armbrecht G, Plesner T, Snowden JA , Nahi H et al (2014) EFFECTS OF SINGLE-AGENT BORTEZOMIB (BTZ) AS POST-TRANSPLANT CONSOLIDATION ON MULTIPLE MYELOMA (MM)-RELATED BONE DISEASE: FIRST RESULTS FROM A MULTICENTER, RANDOMIZED PHASE 2 STUDY. HAEMATOLOGICA, Vol. 99 (pp 362-362) RIS download Bibtex download
  • Parrish C, Morris TCM, Williams C, Cairns DA, Cavenagh J, Snowden JA, Ashcroft J, Cavet J, Hunter H, Bird JM , Chalmers A et al (2014) Stem cells harvested after bortezomib-based re-induction for multiple myeloma relapsing after autologous stem cell transplant (ASCT) and those stored from first induction yield equal outcomes: results from the BSBMT/UKMF Myeloma X (Intensive) Trial. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 165 (pp 62-63) RIS download Bibtex download
  • Owen RG, DeTute DM, Ashcroft AJ, Cairns DA, Fletcher M, Williams C, Cavenagh JD, Snowden JA, Rawstron AC, Parrish C , Morris TC et al (2014) The utility of minimal residual disease (MRD) assessment in post-first relapse re-induction: results from the BSBMT/UKMF Myeloma X (intensive) Trial. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 165 (pp 65-66) RIS download Bibtex download
  • Veys P, Danby R, Vora A, Slatter M, Wynn R, Lawson S, Steward C, Gibson B, Potter M, de la Fuente J , Shenton G et al (2014) UK EXPERIENCE OF UNRELATED CORD BLOOD TRANSPLANTATION IN PAEDIATRIC PATIENTS. BONE MARROW TRANSPLANTATION, Vol. 49 (pp S359-S359) RIS download Bibtex download
  • Snowden J, Marjanovic Z, Badoglio M, Saccardi R, Farge D & Party EBMTADW (2014) EVOLUTION, TRENDS AND LONG TERM OUTCOMES IN HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN AUTOIMMUNE DISEASES (ADS): A RETROSPECTIVE STUDY FROM THE AUTOIMMUNE DISEASES WORKING PARTY (ADWP) OF THE EBMT 1996-2013. BONE MARROW TRANSPLANTATION, Vol. 49 (pp S43-S43) RIS download Bibtex download
  • Snowden J, Danby R, Ruggeri A, Marks D, Hough R, Pagliuca A, Potter M, Russell N, Craddock C, Clark A , Miller P et al (2014) UK EXPERIENCE OF UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) IN ADULTS: A RETROSPECTIVE ANALYSIS ON BEHALF OF EUROCORD AND THE BRITISH SOCIETY OF BLOOD AND MARROW TRANSPLANTATION (BSBMT). BONE MARROW TRANSPLANTATION, Vol. 49 (pp S233-S234) RIS download Bibtex download
  • Parrish C, Morris T, Williams C, Cairns D, Cavenagh J, Snowden JA, Ashcroft J, Cavet J, Hunter H, Bird JM , Chalmers A et al (2014) STEM CELL HARVESTING AFTER RE-INDUCTION WITH A BORTEZOMIB-BASED REGIMEN FOR MULTIPLE MYELOMA RELAPSING AFTER AUTOLOGOUS STEM CELL TRANSPLANT IS FEASIBLE, SAFE AND EFFECTIVE: RESULTS FROM THE BSBMT/UKMF MYELOMA X (INTENSIVE) TRIAL. BONE MARROW TRANSPLANTATION, Vol. 49 (pp S73-S74) RIS download Bibtex download
  • Snowden J, Badoglio M, Farge D & Party EBMTADW (2014) UPDATE OF THE ACTIVITY OF THE EBMT AUTOIMMUNE DISEASES WORKING PARTY (ADWP). BONE MARROW TRANSPLANTATION, Vol. 49 (pp S95-S96) RIS download Bibtex download
  • Cook G, Williams C, Cairns DA, Chalmers A, Cavenagh J, Snowden J, Parrish C, Ashcroft J, Yong K, Cavet J , Hunter H et al (2014) SUPERIOR DURABILITY OF RESPONSE WHEN A SECOND AUTOLOGOUS STEM CELL TRANSPLANT CONSOLIDATES BORTEZOMIB-CONTAINING RE-INDUCTION THERAPY FOR RELAPSED MULTIPLE MYELOMA (MM): FINAL RESULTS FROM THE BSBMT/UKMF MYELOMA X (INTENSIVE) TRIAL. BONE MARROW TRANSPLANTATION, Vol. 49 (pp S72-S72) RIS download Bibtex download
  • Ashcroft J, De Tute RM, Cairns DA, Fletcher M, Owen RG, Williams C, Cavanagh JD, Snowden JA, Rawstron AC, Parrish C , Morris TCM et al (2014) MINIMAL RESIDUAL DISEASE (MRD) ASSESSMENT IN POST-FIRST RELAPSE RE-INDUCTION IS PREDICTIVE FOR TIME TO PROGRESSION (TTP): RESULTS FROM THE BSBMT/UKMF MULTIPLE MYELOMA (MM) X INTENSIVE TRIAL. BONE MARROW TRANSPLANTATION, Vol. 49 (pp S79-S80) RIS download Bibtex download
  • Browett K, Tridente A, Hall J, Sorour Y, Snowden J, Mills GH & Webber S (2013) Mortality predictors in patients with haematological malignancies admitted to critical care. BRITISH JOURNAL OF ANAESTHESIA, Vol. 110(5) (pp 862-863) RIS download Bibtex download
  • Cook G, Williams C, Szubert A, Yong K, Cavet J, Hunter H, Bird J, Bell S, O'Connor S, Cavenagh J , Snowden J et al (2013) A second autologous stem cell transplant induces superior response durability following bortezomib-containing re-induction therapy for relapsed multiple myeloma: results from the BSBMT/UKMF myeloma x (intensive) trial. BONE MARROW TRANSPLANTATION, Vol. 48 (pp S17-S17) RIS download Bibtex download
  • Morris C, Williams C, Bell S, Fletcher M, Szubert A, Yong K, Covet J, Cavenagh J, Snowden J, Ashcroft J , Brown J et al (2013) BSBMT/UKMF myeloma X relapse (intensive) trial: barriers to recruitment and randomization. BONE MARROW TRANSPLANTATION, Vol. 48 (pp S210-S211) RIS download Bibtex download
  • Douglas KW, Hayden P, Hunter H, Johnson P, Malladi R, Paneesha S, Pawson R, Quinn M, Raj K, Richardson D , Robinson S et al (2013) Use of plerixafor to rescue absolute and predicted mobilization failures: a UK and Ireland consensus. BONE MARROW TRANSPLANTATION, Vol. 48 (pp S112-S113) RIS download Bibtex download
  • Morris TCM, Williams C, Bell S, Flrtcher M, Szubert A, Yong K, Cavet J, Cavenagh J, Snowden J, Ashcroft J , Brown J et al (2013) BSBMT/UKMF Myeloma X Relapse (intensive) Trial - challenges in recruitment and randomisation. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 161 (pp 52-52) RIS download Bibtex download
  • Stradwick S, Freemantle N, Snowden J, Rodrigues F & Brereton N (2012) Comparative Effectiveness of Lenalidomide Plus Dexamethasone for the Treatment of Refractory/Relapsed Multiple Myeloma: A Systematic Review and Mixed Treatment Comparison. BLOOD, Vol. 120(21) RIS download Bibtex download
  • Alix J, Blackburn D, Sokhi D, Dalley C, Jessop H, Sharrack B & Snowden J (2012) Pulse high-dose cyclophosphamide in malignant multiple sclerosis may result in successful functional recovery and stem cell mobilisation to enable safe delivery of AHSCT. BONE MARROW TRANSPLANTATION, Vol. 47 (pp S227-S228) RIS download Bibtex download
  • Hummel S, Snowden J, Nield A, McGoldrick R, Harrison S, Swanborough F, Davis J, Goddard Y, Ward S, Ezaydi Y , Morley N et al (2012) Predicting increases in bed capacity for haematopoietic stem cell transplantation or intensive chemotherapy through simulation modelling of ambulatory care. BONE MARROW TRANSPLANTATION, Vol. 47 (pp S278-S278) RIS download Bibtex download
  • Dharmagunawardena RT, Pearce RM, Lee J, Apperley JF, Littlewood T, Wilson KM, Orchard K, Jackson G, Snowden JA, Kirkland K , Cook G et al (2011) A RETROSPECTIVE MULTI-CENTRE STUDY OF THE EFFECTS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION ON PULMONARY FUNCTION. THORAX, Vol. 66 (pp A62-A62) RIS download Bibtex download
  • Dennis M, Goodyear O, Loke J, Jilani N, Siddique S, Ryan G, Khanum R, Snowden J, Griffiths M, Russell NH , Yin J et al (2011) Azacitidine Induces Expansion of Regulatory T Cells and Tumour Specific CD8+T Lymphocytes After Allogeneic Stem Cell Transplantation: A Strategy for Epigenetic Manipulation of a Graft-Versus-Leukemia Response. BLOOD, Vol. 118(21) (pp 152-152) RIS download Bibtex download
  • Marsh JCW, Pearce RM, Koh MB, Tang D, Lim Z, Pagliuca A, Mufti GJ, Snowden J, Vora AJ, Gibson B , Gilleece MH et al (2011) National, Retrospective, Multi-Centre Comparison of Alemtuzumab- Versus ATG-Based Conditioning Regimens in Hematopoietic Stem Cell Transplantation for Aplastic Anemia: A Study From the British Society for Blood and Marrow Transplantation (BSBMT) (CTCR 09-03). BLOOD, Vol. 118(21) (pp 26-26) RIS download Bibtex download
  • Tailor IK, Walker R, Dalley CD, Vora AJ, Collins N & Snowden JA (2011) Umbilical cord blood transplantation (UCBT) in teenagers and adults: Sheffield experience 2005-2010. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 153 (pp 68-69) RIS download Bibtex download
  • Greenfield DM, Ezaydi Y, Cachia E & Snowden J (2011) Endocrine, bone and nutritional 'late effects' in patients with advanced stage multiple myeloma following HSCT and other intensive treatment. BONE MARROW TRANSPLANTATION, Vol. 46 (pp S186-S186) RIS download Bibtex download
  • Daikeler T, Labopin M, Di Gioia M, Abinun M, Alexander T, Miniati I, Gualandi F, Fassas A, Martin T, Schwarze C-P , Wulffraat N et al (2011) Diagnosis of Lupus, age at HSCT and CD34+graft selection are the main risk factors for secondary autoimmune diseases occurring after HSCT for autoimmune diseases: a retrospective study of the EBMT Autoimmune Disease Working Party. BONE MARROW TRANSPLANTATION, Vol. 46 (pp S84-S85) RIS download Bibtex download
  • Daikeler T, Labopin M, di Gioia M, Abinun M, Alexander T, Miniati I, Gualandi F, Fassas A, Martin T, Schwarze C-P , Wulffraat N et al (2010) Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study. BLOOD, Vol. 116(21) (pp 959-960) RIS download Bibtex download
  • Martinez C, Canals C, Alessandrino EP, Karakasis D, Pulsoni A, Leone G, Trneny M, Snowden J, Apperley J, Milpied N , Bossi A et al (2010) RELAPSE OF HODGKIN'S LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): IDENTIFICATION OF PROGNOSTIC FACTORS PREDICTING OUTCOME. HAEMATOLOGICA, Vol. 95 (pp S26-S26) RIS download Bibtex download
  • Oo N, Jones DA, Snowden J & El-Ghariani K (2010) Autologous peripheral progenitor cell harvesting in haematology patients: One centre experience. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 149 (pp 67-67) RIS download Bibtex download
  • Cachia E, Eiser C, Beeken R, McAtamney K, Greenfield D, Ezaydi Y, Walmsley S, Ross RJ, Coleman R, Ahmedzai SH , Snowden J et al (2010) A study of pain, peripheral neuropathy and psychosocial late effects in patients with intensively treated advanced multiple myeloma. BONE MARROW TRANSPLANTATION, Vol. 45 (pp S396-S396) RIS download Bibtex download
  • Cachia E, Greenfield D, Ezaydi Y, Baxter L, Ahmedzai SH, Eiser C, Coleman R, Ross R, Snowden J & Grp LE (2010) A study of the endocrine, metabolic and nutritional late effects in patients with advanced intensively treated multiple myeloma. BONE MARROW TRANSPLANTATION, Vol. 45 (pp S396-S397) RIS download Bibtex download
  • Snowden JA (2010) CHOICE OF CONDITIONING REGIMEN. BONE MARROW TRANSPLANTATION, Vol. 45 (pp S3-S3) RIS download Bibtex download
  • Nield A, Charley C, Dalley C, Davis J, Goddard Y, Salt M, Snowden J, Sprigens N & Ward S (2009) High-dose melphalan with stem cell rescue in the ambulatory care setting: the process to enable the concept to become a realistic treatment option. BONE MARROW TRANSPLANTATION, Vol. 43 (pp S319-S319) RIS download Bibtex download
  • Fredrick L, Beeken R, Taylor N, Eiser C, Wright J, Snowden J & Dalley C (2009) Quality of life in adult survivors of blood and marrow transplantation correlates strongly with physical and psychological late effects of treatment: a mixed methods approach. BONE MARROW TRANSPLANTATION, Vol. 43 (pp S180-S180) RIS download Bibtex download
  • Kuhl JS, Kohler W, Bandmann O, Buchholz S, Hemmati P, Snowden J, Sokolowski P, Stadler M, Terwey T & Arnold R (2009) Bone marrow transplantation in adult cerebral X-linked adrenoleukodystrophy: an update. BONE MARROW TRANSPLANTATION, Vol. 43 (pp S182-S183) RIS download Bibtex download
  • Alfred A, Mahmood S, Jones DA, Hess D, Wright J, Snowden JA & Mijovic A (2009) High-dose G-CSF is safe and effective for mobilisation of haemopoietic cells for autologous stem cell transplantation with clinical utility in the majority of sub-optimal mobilisers. BONE MARROW TRANSPLANTATION, Vol. 43 (pp S114-S115) RIS download Bibtex download
  • Craddock C, Tauro S, Buckley L, Kottaridis P, Thelouli E, Thomson K, Milligan D, Liakopoulou E, Snowden J, Marsh J , Hunter A et al (2008) PATIENT AND DONOR CHARACTERISTICS DETERMINE OUTCOME AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol. 93 (pp 354-354) RIS download Bibtex download
  • Craddock CF, Tauro S, Gregory JE, Buckley L, Ward J, Kottaridis P, Thelouli E, Thomson K, Milligan D, Das-Gupta E , Liakpopoulou E et al (2007) Factors predicting long term survival after reduced intensity allogeneic stem cell transplantation in acute myeloid leukemia. BLOOD, Vol. 110(11) (pp 103A-103A) RIS download Bibtex download
  • Sorour Y, Robinson K, Hurlstone P, Ei-Ghariani K, Lobo A & Snowden JA (2006) High-dose immune immunoablative therapy and autologous stem cell transplantation in severe resistant Crohn's disease: profound response for 18 months followed by treatable relapse. BONE MARROW TRANSPLANTATION, Vol. 37 (pp S341-S341) RIS download Bibtex download
  • Alfred A, Throssell D, Ezaydi Y, Jones B, Reilly JT & Snowden JA (2006) Successful myeloablative allogeneic haemopoietic stem cell transplantation in a patient with end-stage renal failure on haemodialysis. BONE MARROW TRANSPLANTATION, Vol. 37 (pp S350-S350) RIS download Bibtex download
  • Chantry AD, Snowden JA, Craddock C, Marks DM & Transplantat BSBM (2006) Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukaemia in second remission: a British Society of Bood and Marrow Transplantation Registry study. BONE MARROW TRANSPLANTATION, Vol. 37 (pp S9-S10) RIS download Bibtex download
  • Feyler S, Rawstron A, Jackson G, Snowden J, Hawkins K & Johnson RJ (2005) Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study.. BLOOD, Vol. 106(11) (pp 190A-190A) RIS download Bibtex download
  • Feyler S, Jackson G, Rawstron A, El-Sherbiny YM, Snowden JA & Johnson RJ (2003) Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study.. BLOOD, Vol. 102(11) (pp 691A-691A) RIS download Bibtex download
  • Ponchel F, Papadaki H, Bingham S, Verburg R, Moore J, Protheroe A, McGonagle D, Snowden J, Van-Laar J, Markham AF , Emery P et al (2003) Il-7 and therapy-induced lymphopenia in RA. ANNALS OF THE RHEUMATIC DISEASES, Vol. 62 (pp 164-164) RIS download Bibtex download
  • Frost L, Wilson G, Goodeve A, Gerrard M, Snowden J, Peake I & Vora A (1999) Relapsing precursor B-ALL presenting as CD-10 positive isolated extramedullary lymphoma.. BLOOD, Vol. 94(10) (pp 219B-219B) RIS download Bibtex download
  • Kass-Iliyya L, Snowden JA, Thorpe A, Jessop H, Chantry AD, Sarrigiannis PG, Hadjivassiliou M & Sharrack B () Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience. Journal of Neurology RIS download Bibtex download

Other

Grants
  • NIHR EME, HTA & Research for Patient Benefit.
  • Cure Leukaemia, Trial Acceleration Programme (TAP). 
  • Sheffield Hospitals Charity. 
  • Bloodwise (formerly Leukaemia and Lymphoma Research/Leukaemia Research Fund). 
  • Cancer Research UK. 
  • Macmillan Cancer Support.
  • National Institutes of Health/National Cancer Institute. 
  • Health Foundation SHINE Award. 
  • Healthcare Quality Improvement Partnership (2010-13). 
  • Kay Kendall Leukaemia Fund. 
  • Myeloma UK Research Grant Programme. 
  • Weston Park Hospital Cancer Appeal. 
  • Arthritis Research Campaign.

Postgraduate awards 

Teaching activities
  • I have been actively involved in teaching and lecturing in undergraduate medicine locally, nationally and internationally. University of Sheffield examiner for BMedSci students.
  • Clinical co-supervisor and personal tutor for a large number of doctorate (PhD and MD) students at The University of Sheffield and UCL. 
  • Examiner for PhDs at The University of Sheffield, and external at University of Birmingham, Newcastle University, and University of Oxford. 
  • Educational supervision of postgraduate specialist training of numerous specialist trainees through the Membership of Royal College of Physicians and Pathologists examinations. 
  • Examiner for the Royal College of Pathologists. 
Professional activities

Nationally and internationally, I have delivered on key leadership roles in the areas of quality and accreditation (JACIE, NICE), NHS R&D (NCRI), education/research (BSBMT National Executive & EBMT Board/Scientific Council, and in NHS England National Specialised Commissioning for BMT (as chair and member) and Chair of the National Clinical CART Panel (NCCP) for acute lymphoblastic leukaemia and Co-Lead Clinician for Haemato-Oncology of the North East & Yorkshire region Genomic Laboratory Hub (GLH).

Sheffield Teaching Hospitals NHS Foundation Trust (STHFT)

  • Director of Blood and Marrow Stem Cell Transplant Programme (2002-present). 
  • Lead Clinician for Haemato-Oncology, STHFT Cancer Services Steering Group (2005-2007) and Cancer Executive (2002-2005).
  • Lead Clinician in Haematology Late Effects Service (2008-present).

University of Sheffield (UoS) and University College London (UCL)

  • Honorary Professor, Department of Oncology & Metabolism, UoS (from November 2013).
  • Honorary Reader, Department of Oncology (2010-2013).
  • Honorary Clinical Professor, Department of Haematology, Cancer Institute, UCL (from June 2016 to end 2024).

Regional NHS Cancer Roles

  • Lead Clinician, Network Site Specific Group (NSSG) for Haemato-Oncology (2007-10), and acting chair/vice-chair of NSSG (2014-15). 
  • Chair, NSSG Working Party for the Haemato-Oncology Diagnostic Service (2005-07).
  • Co-Lead Clinician for Haematology-Oncology in the NHS England Genomic Laboratory Hub (GLH) for North-East & Yorkshire (NEY) region, appointed March 2019. 

National roles and responsibilities 

  • National Cancer Research Institute (NCRI) Clinical Studies Group in Haematological Oncology: Member by appointment (2008-17) and Chair of the Supportive Care, Transfusion & Late Effects Working Party (since 2015-17), Member of Aplastic Anaemia Working Group (2017-19). 
  • National Confidential Enquiry into Patient Outcomes and Death (NCEPOD), Member of Expert Working Group for Systemic Anti-Cancer Chemotherapy, from 2006 until publication of report ‘Systemic Anti-Cancer Therapy: For better, for worse?’ in 2008.
  • UK Myeloma Forum Executive, Elected Member, 2009-12, renewed 2012-15.
  • Chair (2016-20) and previous Member of NHS England Clinical Reference Group (CRG) for National Specialised Commissioning of BMT Services (2011-2016). 
  • BSBMTCT Executive Committee Member (elected) 2012-2015, Secretary (elected) 2015-18, President-elect (elected) 2019-20, and President from 2021-22.
  • Member, UKNEQAS Leucocyte Immunophenotyping Steering Committee 2014-present.
  • NICE
    • Expert clinical member of NICE Guideline Development Group in Myeloma (NG35) 2014-15.
    • Clinical Lead, NICE IOG for Haematological Cancers (update, NG47), 2015-16.
    • Clinical Co-Lead for COVID-19 rapid NICE Guidance in HSCT (NG164), 2020-21.

International roles and responsibilities

  • Secretary to the EBMT (2020-24) 
  • Chair of the European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (2016-20), having been Secretary (2010-16).
  • EBMT JACIE Committee, as Chair (2015-20) and Medical Director (2012-16).
  • JACIE Committee Chair (from April 2015-July 2020) & JACIE Medical Director (April 2012-April 2016).
  • Worldwide Network for Blood and Marrow Transplantation (WBMT) Executive Member (2015-).

Other Working Parties and Guidelines Groups 

  • EBMT Transplant Complications Working Party (TCWP) and Severe Aplastic Anaemia Working Party (SAAWP). 
  • BSH/UKMF Myeloma Guidelines Group (Lead in Supportive Care and Long Term Monitoring Guidelines).
  • BSH Aplastic Anaemia Guidelines Group 2014-present.
  • NICE Guidelines in Myeloma (NG35), Clinical Expert Advisor 2014-16.
  • NICE Improving Outcomes Guidance in Haematological Cancers (NG47), Clinical Lead 2015-16.
  • NICE Rapid Guidance for COVID and Haematopoeitic Stem Cell Transplantation (NG164), Clinical Lead 2020.

Scientific Organising Committees, Scientific Journal Editorship and Peer Review Work

  • Scientific/organising committee membership e.g. many Annual EBMT Congresses and Educational Events & and BSBMTCT educational and scientific days.
  • Associate Editor, Current Research in Translational Medicine (2013-present), Associate Editor Frontiers in Immunology specialty section ‘Alloimmunity and Transplantation’ (2021-).
     
  • Editorial Board Member, Blood Advances (2021-present), International Journal of Laboratory Haematology (2006-2021).
  • Guest Editorships, Frontiers in Immunology Special Edition on ‘Biomarkers in Graft versus Host Disease’ 2019-20, Clinical Medicine (Journal of the Royal College of Physicians of London) for Haematology CME 2018, Current Opinion in Supportive and Palliative Care 2017 special edition on Haematology.
  • Peer reviewer for scientific journals, conference abstracts and international, national and local grant applications.
  • Peer reviewer for University Professorship promotions.

Clinical Trials Networks and Committees

  • Principal Investigator for Clinical Trials Networks (CTNs): 
    • Cure Leukaemia Therapy Acceleration Programme (TAP). 
    • IMPACT BMT CTN (affiliate member).
  • Membership of Trial Management Groups, Data Monitoring and Ethics Committee and Trial Steering Groups. 

Media and related work

  • Radio and TV as an expert opinion on haemato-oncology and stem cell transplantation, including collaborative work on Haematopoietic Stem Cell Transplantation in Multiple Sclerosis was featured increasingly in media leading to a BBC Panorama documentary ‘Can You Stop My MS?aired in 2016 to estimated 2.4 million live, with subsequent broadcast interview coverage and other on-line coverage reaching an estimated 180 million worldwide. 
  • Also featured in many national newspapers and their on-line versions.
Examples of invited lectures, chairing and organising committees for last 5 years

2016

  • Organiser, Invited speaker, EBMT ‘Educational Meeting of Autoimmune Diseases Working Party’, Berlin, January 2016.
  • Invited Speaker, Autoimmune Diseases Meeting, Porto, Portugal, January 2016.
  • Organser, Invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT Meeting, Valencia, April 2016.
  • Invited Speaker, XXXVI World Congress of the International Society of Hematology hosted by the British Society for Haematology, Glasgow, April 2016.
  • Invited Speaker, EBMT Highlights, Jeddah, Saudi Arabia, May 2016.
  • Invited Speaker, Uppsala University, Sweden, May 2016.
  • Invited Speaker, Department of Neurology, Oxford University, June 2016.
  • Invited Speaker, Myeloma UK Symposium, Birmingham, September 2016.
  • Organiser, Invited speaker, BSBMT Annual Educational Meeting, London, November 2016.
  • Organiser, Invited speaker, EBMT ‘Educational Meeting of Autoimmune Diseases and Severe Aplastic Anaemia Working Parties’, Paris, November 2016.
  • Organiser, Invited speaker, ‘Late Effects in Cancer Survivors’, Royal College of Physicians of London, November 2016.
  • Invited Speaker, Autoimmunity and Immunodeficiency Diseases Conference, Moscow, Russia, December 2016.

2017

  • Invited speaker and session chair, Tandem Meeting of the American Society for Blood and Marrow Transplantation (ASBMT) and Centre for International Bone Marrow Transplant Research (CIBMTR), Orlando, FL, USA, February 2017.
  • Organiser, Invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT Congress, Marseille, March 2017.
  • Organiser, Invited Speaker, NCRI Haemato-oncology Annual Trials Day, May 2017.
  • Invited Speaker, ‘Inflammation, breaking down Silos’, Oxford University, June 2017.
  • Invited Speaker, University of Jordan, October 2017.
  • Organiser, Invited speaker, BSBMT Annual Educational Meeting, London, November 2017.
  • Organiser, Invited speaker, EBMT ‘Educational Meeting of Autoimmune Diseases and Inborn Errors Working Parties’, Newcastle, November 2017.

2018

  • Invited Speaker, Annual ECCO Congress, Vienna, February 2018.
  • Organiser, Invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT Congress, Lisbon, March 2018.
  • Invited speaker, BSBMT Annual Scientific Meeting, London, May 2018.
  • Invited Speaker, EBMT Highlights, Riyadh, Saudi Arabia, May 2018.
  • Invited Speaker, EBMT Highlights, Delhi, India, May 2018.
  • Organiser, Invited speaker, EBMT International Training Course in BMT, September, 2018.
  • Organiser, Invited speaker/chair, BSBMT Annual Educational Meeting, London, October 2018.
  • Invited Speaker, UKE Hamburg-Eppendorf, Germany, October 2018.
  • Invited Speaker, Myelin Meeting, Leipzig, Germany, October 2018.
  • Invited speaker, Royal College of Physicians, London, October 2018.
  • Organiser, Invited speaker, EBMT ‘Educational Meeting of Autoimmune Diseases and Severe Aplastic Anaemia Working Parties’, Florence, November 2018.

2019

  • Invited speaker, Royal Society of Medicine, London, March 2019.
  • Organiser, Invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT Congress, Frankfurt, March 2019.
  • Invited speaker, British Society for Cell and Gene Therapy (BSCGT) Annual Meeting, Sheffield, June 2019.
  • Invited speaker, 61st National Congress of the Spanish Hematology and Hemotherapy Society and 35th National Congress of the Spanish Society of Thrombosis and Hemostasis, Valencia, October 2019.
  • Invited speaker, COSTEM (Controversies in Stem Cell Transplantation) Meeting, Berlin, October 2019.
  • Organiser, Invited speaker, EBMT ‘Educational Meeting of Autoimmune Diseases Working Party’, Berlin, October 31-November 1, 2019.
  • Invited speaker, international conference “Stem cell transplantation for treatment of autoimmune diseases: sharing the experience”, Moscow, November, 2019.
  • Invited speaker, organiser, national conference of the Intercollegiate Committee on Haematology “Updates, Controversies, Uncertainties”, Royal College of Pathologists, London, December 17, 2019.

2020

  • Invited speaker 4th French International Symposium on CAR T Cells, Faculty of Medicine and Lille University Hospital, Lille, France January 2020.
  • Organiser, invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT Congress, Madrid, re-scheduled as virtual meeting to August 31-September 2 2020.
  • Organiser, session chair, EBMT ‘Educational Meeting of Autoimmune Diseases Working Party’, Virtual Conference, September 24-25 2020.

2021

  • Organiser, invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT ‘Virtual’ Congress, March 14-17 2021.
  • Organiser, session chair, EBMT ‘Educational Meeting of Autoimmune Diseases Working Party’, Virtual Conference, September 23-24 2021.
  • Invited speaker and session chair, ‘EBMT Covid-19 Summit’, Virtual Conference, June 29 –July1, 2021.
  • Invited speaker (virtual), Departments of Haematology and Neurology, Leeds Teaching Hospitals, September 21, 2021.
  • Organiser, session chair, EBMT ‘Educational Meeting of Autoimmune Diseases Working Party’, Virtual Conference, September 23-24, 2021.
  • Invited speaker, UK Primary Immunodeficiency Network (UKPIN) Meeting, Sheffield, November 2, 2021.

2022

  • Invited speaker MS Academy - Live Webinar (with Prof Basil Sharrack) ‘UK stem cell transplantation in MS (the StarMS trial), January 27, 2022.
  • Invited virtual lecture to Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California, Irvine, February 9, 2022.
  • Invited speaker (virtual) University College Dublin Centre for Arthritis Research Seminar, February 18, 2022.
  • Organiser, invited Speaker, Sessional Chair, 9th Annual ECTRIMS Focused Workshop, March 10-11, 2022 on  'Autologous haematopoietic stem cell transplantation for treatment of MS and related diseases'.
  • Organiser, invited Speaker, Abstract Reviewer, Sessional Chair, Annual EBMT ‘Virtual’ Congress, March 19-23, 2022.
  • Invited Speaker, Northern Connections MS Meeting, Edinburgh, The Royal College of Physicians of Edinburgh, June 10, 2022.
  • Invited speaker, 30th Congress of the Polish Society of Haematology and Transfusion Medicine September 8-10, 2022.
  • Invited speaker, MS At the Limits Meeting, Edinburgh, Royal College of Physicians of London, September 19, 2022.
  • Organiser, session chair, EBMT ‘Educational Meeting of Autoimmune Diseases Working Party’, Royal College of Pathologists, London, September 24-25, 2022.